logo
Computer simulations reveal the first wheel was invented nearly 6,000 years ago

Computer simulations reveal the first wheel was invented nearly 6,000 years ago

Fast Company9 hours ago

Imagine you're a copper miner in southeastern Europe in the year 3900 BCE. Day after day you haul copper ore through the mine's sweltering tunnels.
You've resigned yourself to the grueling monotony of mining life. Then one afternoon, you witness a fellow worker doing something remarkable.
With an odd-looking contraption, he casually transports the equivalent of three times his body weight on a single trip. As he returns to the mine to fetch another load, it suddenly dawns on you that your chosen profession is about to get far less taxing and much more lucrative.
What you don't realize: You're witnessing something that will change the course of history—not just for your tiny mining community, but for all of humanity.
Despite the wheel's immeasurable impact, no one is certain as to who invented it, or when and where it was first conceived. The hypothetical scenario described above is based on a 2015 theory that miners in the Carpathian Mountains (now Hungary) first invented the wheel nearly 6,000 years ago as a means to transport copper ore.
The theory is supported by the discovery of more than 150 miniaturized wagons by archaeologists working in the region. These pint-size, four-wheeled models were made from clay, and their outer surfaces were engraved with a wickerwork pattern reminiscent of the basketry used by mining communities at the time. Carbon dating later revealed that these wagons are the earliest known depictions of wheeled transport to date.
This theory also raises a question of particular interest to me, an aerospace engineer who studies the science of engineering design. How did an obscure, scientifically naive mining society discover the wheel, when highly advanced civilizations, such as the ancient Egyptians, did not?
A controversial idea
It has long been assumed that wheels evolved from simple wooden rollers. But until recently no one could explain how or why this transformation took place. What's more, beginning in the 1960s, some researchers started to express strong doubts about the roller-to-wheel theory.
After all, for rollers to be useful, they require flat, firm terrain and a path free of inclines and sharp curves. Furthermore, once the cart passes them, used rollers need to be continually brought around to the front of the line to keep the cargo moving. For all these reasons, the ancient world used rollers sparingly. According to the skeptics, rollers were too rare and too impractical to have been the starting point for the evolution of the wheel.
But a mine—with its enclosed, human-made passageways—would have provided favorable conditions for rollers. This factor, among others, compelled my team to revisit the roller hypothesis.
A turning point
The transition from rollers to wheels requires two key innovations. The first is a modification of the cart that carries the cargo. The cart's base must be outfitted with semicircular sockets, which hold the rollers in place. This way, as the operator pulls the cart, the rollers are pulled along with it.
This innovation may have been motivated by the confined nature of the mine environment, where having to periodically carry used rollers back around to the front of the cart would have been especially onerous.
The discovery of socketed rollers represented a turning point in the evolution of the wheel and paved the way for the second and most important innovation. This next step involved a change to the rollers themselves. To understand how and why this change occurred, we turned to physics and computer-aided engineering.
Simulating the wheel's evolution
To begin our investigation, we created a computer program designed to simulate the evolution from a roller to a wheel. Our hypothesis was that this transformation was driven by a phenomenon called ' mechanical advantage.' This same principle allows pliers to amplify a user's grip strength by providing added leverage. Similarly, if we could modify the shape of the roller to generate mechanical advantage, this would amplify the user's pushing force, making it easier to advance the cart.
Our algorithm worked by modeling hundreds of potential roller shapes and evaluating how each one performed, both in terms of mechanical advantage and structural strength. The latter was used to determine whether a given roller would break under the weight of the cargo. As predicted, the algorithm ultimately converged upon the familiar wheel-and-axle shape, which it determined to be optimal.
During the execution of the algorithm, each new design performed slightly better than its predecessor. We believe a similar evolutionary process played out with the miners 6,000 years ago.
It is unclear what initially prompted the miners to explore alternative roller shapes. One possibility is that friction at the roller-socket interface caused the surrounding wood to wear away, leading to a slight narrowing of the roller at the point of contact. Another theory is that the miners began thinning out the rollers so that their carts could pass over small obstructions on the ground.
Either way, thanks to mechanical advantage, this narrowing of the axle region made the carts easier to push. As time passed, better-performing designs were repeatedly favored over the others, and new rollers were crafted to mimic these top performers.
Consequently, the rollers became more and more narrow, until all that remained was a slender bar capped on both ends by large discs. This rudimentary structure marks the birth of what we now refer to as 'the wheel.'
According to our theory, there was no precise moment at which the wheel was invented. Rather, just like the evolution of species, the wheel emerged gradually from an accumulation of small improvements.
This is just one of the many chapters in the wheel's long and ongoing evolution. More than 5,000 years after the contributions of the Carpathian miners, a Parisian bicycle mechanic invented radial ball bearings, which once again revolutionized wheeled transportation.
Ironically, ball bearings are conceptually identical to rollers, the wheel's evolutionary precursor. Ball bearings form a ring around the axle, creating a rolling interface between the axle and the wheel hub, thereby circumventing friction. With this innovation, the evolution of the wheel came full circle.
This example also shows how the wheel's evolution, much like its iconic shape, traces a circuitous path—one with no clear beginning, no end, and countless quiet revolutions along the way.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pola-R-GemOx Boosts Survival in R/R DLBCL
Pola-R-GemOx Boosts Survival in R/R DLBCL

Medscape

timean hour ago

  • Medscape

Pola-R-GemOx Boosts Survival in R/R DLBCL

MILAN — Combining polatuzumab vedotin (Pola) with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improves survival outcomes in patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to new data from the phase 3 POLARGO trial. Presented by Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, New Brunswick, New Jersey, here at the European Hematology Association (EHA) 2025 Annual Meeting, the study showed a 40% reduction in the relative risk of death with Pola-R-GemOx versus R-GemOx alone. "These are the gems of the congress," said Martin Dreyling, MD, scientific program committee chair for EHA2025, who presided over the session, describing this and similar studies as potentially practice-changing. Improved OS and PFS Matthew Matasar, MD The global trial enrolled 270 patients with R/R DLBCL who were ineligible for autologous stem cell transplant, had received at least one prior line of therapy, and had not previously been treated with Pola. Of those, 255 were randomized 1:1 to receive Pola-R-GemOx or R-GemOx every 21 days for up to 8 cycles. Patients were stratified by age (≤70 vs >70 years), prior lines of therapy (1 vs ≥2), and response to the most recent treatment (relapsed vs refractory). Baseline characteristics were well-balanced between groups; two thirds were treated in the second-line setting and most had refractory disease. At a median follow-up of 24.6 months, the primary endpoint was met: median overall survival (OS) was 19.5 months with Pola-R-GemOx versus 12.5 months with R-GemOx (hazard ratio [HR], 0.60; 95% CI, 0.43-0.83; P = .0017). Two-year OS was 44.0% versus 33.2%, respectively. Progression-free survival (PFS) also significantly improved at a median follow-up of 18.7 months (HR, 0.37; 95% CI, 0.27-0.51; P = .0001), increasing from 2.7 months to 7.4 months. The 12-month PFS was 36.6% for Pola-R-GemOx and 17.9% for R-GemOx. Response rates were nearly double in the experimental group. The overall response rate (ORR) was 52.7% versus 24.6% and the complete response rate was 40.3% versus 19.0%, respectively, as assessed by an independent review committee. Subgroup and Safety Analyses The OS benefit was consistent across subgroups, including those with and without bulky disease, and among both primary refractory and non-refractory patients. Notably, survival benefit was seen in both activated B-cell (ABC) and germinal center B-cell (GCB) subtypes — contrary to prior findings from the POLARIX trial, which had suggested preferential benefit in the ABC subtype. Matasar emphasized the robustness of the results, noting that patients receiving R-GemOx underwent more subsequent lines of therapy, ruling out confounding by post-progression treatment access. However, the enhanced efficacy came with increased toxicity. Patients in the Pola-R-GemOx group received a median of 7.5 cycles versus 4 cycles in the R-GemOx group. Treatment discontinuations due to adverse events (AEs) were more common with Pola-R-GemOx (23.4% vs 8.0%). Grade 3-4 AE rates were similar (57.0% vs 58.4%), though thrombocytopenia and infections were more frequent in the experimental group. Infections were the leading cause of grade 5 AEs, including 10 COVID-related deaths (seven during treatment, three after completion). "It's worth remembering that the study was conducted during the peak of the COVID-19 pandemic," Matasar noted. Peripheral neuropathy, an expected AE due to overlapping neurotoxicities of Pola and oxaliplatin, was observed in 57.0% of patients receiving Pola-R-GemOx versus 28.8% with R-GemOx. Most cases were grade 1, but 3.9% of patients in the experimental group had grade 3 events. "Peripheral neuropathy was not permanent in all patients, approximately half of the patients did experience improvement in neuropathy by the time of study closure, and approximately one third of patients had complete resolution," Matasar reported. A Role in Bridging Therapy? Frank Leebeek, MD, PhD Commenting to Medscape Medical News, Frank Leebeek, MD, PhD, chair of hematology at Erasmus University, Rotterdam, Netherlands, who was not involved in the trial, said: "This is very important. Prognosis remains poor for patients with R/R DLBCL who cannot receive or are ineligible for transplant." He welcomed the new option in the arsenal of treatments for this disease. Concluding his presentation, Matasar stressed the importance of having different tools. "Some patients will be appropriate for CAR-T, some for bispecific antibodies, some will have access to neither and benefit from ADC destination therapy. Pola-R-GemOx represents an alternative treatment option," he said. Leebeek noted that Pola-R-GemOx may serve as a bridge therapy to CAR-T because it does not deplete the T-cell population. "Achieving complete remission after relapse is challenging," he said, "and other regimens can impair the T-cell pool, while this one doesn't." The study was funded by F. Hoffmann-La Roche. Matasar has disclosed financial relationships with ADC Therapeutics, AbbVie, Arvinas, AstraZeneca, Bayer, BMS, Genmab, Ipsen, J&J, Kite, Novartis, Regeneron, Roche, and Pfizer, and research support from Allogene, Arvinas, Bayer, Cellectis, Genentech, J&J, Pfizer, Pharmacyclics, Regeneron, and Roche. He has reported serving as a consultant for AbbVie, Allogene, Arvinas, Bayer, BMS, Genentech, Genmab, Kite, Novartis, Pfizer, and Roche, and being a current equity holder of Merck. Leebeek has reported no relevant financial relationships.

A Mix of These Specific Foods Could Help You Avoid Chronic Disease
A Mix of These Specific Foods Could Help You Avoid Chronic Disease

Yahoo

time3 hours ago

  • Yahoo

A Mix of These Specific Foods Could Help You Avoid Chronic Disease

For the good of your health, you might want to favor a wider mix of flavonoids in your diet. These natural plant compounds – found in teas, berries, apples, and dark chocolate – have been linked to longer life and a lower risk of disease, new evidence shows. In particular, it was the broader range of flavonoids that made a difference in this research, not just the higher quantity of them. Flavonoids have previously been connected to anti-inflammatory effects in the body, and reductions in the risk of weight gain, cardiovascular disease, and vision loss. An international team of researchers analyzed data on 124,805 adults in the UK, aged 40 or over. They looked for links between the self-reported diets of the participants and their health, over several years. "We have known for some time that higher intakes of dietary flavonoids, powerful bioactives naturally present in many foods and drinks, can reduce the risk of developing heart disease, type 2 diabetes, and neurological conditions like Parkinson's," says nutritional scientist Aedín Cassidy from Queen's University Belfast in Northern Ireland. "This study is significant as the results indicate that consuming a higher quantity and wider diversity has the potential to lead to a greater reduction in ill health than just a single source." Black and green teas were the most common provider of flavonoids in the study, drunk by two-thirds of the participants. Other sources included apples, red wine, grapes, berries, dark chocolate, oranges, satsumas, and orange juice. The statistics showed that participants whose diets had the widest diversity of flavonoid foods had a lower risk of all-cause mortality, and of numerous health complications. While the data doesn't prove direct cause and effect, the strong suggestion is that mixing your flavonoids is good for you. "Flavonoid intakes of around 500 milligram a day were associated with a 16 percent lower risk of all-cause mortality, as well as around a 10 percent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease," says nutrition scientist Benjamin Parmenter from Edith Cowan University in Australia. "That's roughly the amount of flavonoids that you would consume in two cups of tea." Even when consuming the same total amount of flavonoids, those who consumed the widest diversity had even lower risk of these diseases, the researchers found. The top fifth of the participants in terms of diversity of flavonoid intake saw reductions of around 6-20 percent in the risk of conditions like type 2 diabetes, cancer, and neurodegenerative disease, compared to the bottom fifth. With that in mind, the researchers are recommending a mix of flavonoid-rich food and drink, every day. If you want to set yourself a challenge, the top flavonoid consumers in this study were snacking on 19 different types per day. "Eating fruits and vegetables in a variety of colors, including those rich in flavonoids, means you're more likely to get the vitamins and nutrients you need to sustain a healthier lifestyle," says nutrition scientist Tilman Kuhn from the Medical University of Vienna in Austria. The research was published in Nature Food. One Fitness Accessory Makes You Up to 7 Times More Likely to Stay Active Study Reveals How Much Exercise You Need Each Week to Control Blood Pressure A Toxicologist Reveals The Surprising Truth About Black Mold

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Associated Press

time6 hours ago

  • Associated Press

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congressdescribe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin (TSLP) receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress taking place June 13-16, 2025, in Glasgow, United Kingdom. TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective treatment approach. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. Upstream is developing verekitug in multiple severe respiratory diseases including severe asthma, COPD, and CRSwNP. Verekitug is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. 'These data reinforce our belief in the differentiated profile of verekitug, as the model elucidates important biologic parameters that drive the differentiated rapid, substantial and sustained treatment effects observed through TSLP receptor inhibition with verekitug,' said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development of Upstream Bio. 'We look forward to further assessing the potential translation of this unique mechanism into clinical benefit in patients with severe respiratory diseases, first with top-line Phase 2 clinical data in CRSwNP in the third quarter of this year followed by data in severe asthma in the first half of 2026.' Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows: A digital version of the presentation can be found on the Upstream Bio website. About TSLP and TSLPR Blockade Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy. TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (TSLPR) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. About Verekitug Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. Verekitug is currently being evaluated in two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials, the VALIANT trial in patients with severe asthma (NCT06196879) and the VIBRANT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT06164704). Upstream Bio is also initiating a Phase 2 clinical trial (NCT06981078) of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation. Three clinical trials have been completed for verekitug, including a Phase 1 single-ascending dose (SAD) clinical trial and a Phase 1b multiple-ascending dose (MAD) clinical trial. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent pharmacokinetic profile and high subcutaneous bioavailability. About Upstream Bio Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'continue,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'predict,' 'project,' 'seeks,' 'should,' 'target,' 'will' and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; expectations for future discussions with regulatory authorities and the potential of the endpoints of the Company's clinical trials to produce data that could support submissions for product approval; expectations regarding the differentiation, safety, efficacy or tolerability of verekitug; expectations regarding the translation of pharmacology modeling data of verekitug to clinical effects; and assessments comparing non-head-to-head clinical data of verekitug to published data for tezepelumab. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio's ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio's ability to fund its development activities and achieve development goals; Upstream Bio's dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio's ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio's financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio's competitors and industry; and other risks and uncertainties described in greater detail under the caption 'Risk Factors' in Upstream Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio's views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store